Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Artemis Pharmaceuticals has signed an agreement with Bristol-Myers Squibb to generate genetically-engineered rodent models for use by the US drugmaker in its discovery research activities.
Subscribe to our email newsletter
The rodent models will carry selected genetic mutations and will be used for the validation of novel drug screening targets.
Such targets are used to identify new compounds and therapies for the treatment of diseases for various indications in humans. In vivo validation of disease related drug targets and data generated from them, are increasingly considered to be vital for the success of innovative drug discovery programs.
The generation of the in vivo rodent models will be based on Artemis’ proprietary ArteMice and ArteMice conditional technologies. These technologies enable the introduction of genetic sequences containing the CreER gene switch for conditional gene knockout and the creation of humanized conditional mutants in which rodent genes are replaced by their human orthologues.